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OBJECTIVE—Metformin has been well characterized in vitro
as a substrate of liver-expressed organic cation transporters
(OCTs). We investigated the gene expression and protein levels
of OCT-1 and OCT-2 in adipose tissue and during adipogenesis
and evaluated their possible role in metformin action on
adipocytes.
RESEARCH DESIGN AND METHODS—OCT1 and OCT2
gene expressions were analyzed in 118 adipose tissue samples
(57 visceral and 61 subcutaneous depots) and during human
preadipocyte differentiation. To test the possible role of OCT1
mediating the response of adipocytes to metformin, cotreat-
ments with cimetidine (OCT blocker, 0.5 and 5 mmol/l) and
metformin were made on human preadipocytes and subcutane-
ous adipose tissue (SAT).
RESULTS—OCT1 gene was expressed in both subcutaneous
and visceral adipose tissue. In both fat depots, OCT1 gene
expression and protein levels were signiﬁcantly increased in
obese subjects. OCT1 gene expression in isolated preadipocytes
signiﬁcantly increased during differentiation in parallel to adipo-
genic genes. Metformin (5 mmol/l) decreased the expression of
lipogenic genes and lipid droplets accumulation while increasing
AMP-activated protein kinase (AMPK) activation, preventing
differentiation of human preadipocytes. Cotreatment with cime-
tidine restored adipogenesis. Furthermore, metformin decreased
IL-6 and MCP-1 gene expression in comparison with differenti-
ated adipocytes. Metformin (0.1 and 1 mmol/l) decreased adipo-
genic and inﬂammatory genes in SAT. OCT2 gene expression was
not detected in adipose tissue and was very small in isolated
preadipocytes, disappearing during adipogenesis.
CONCLUSIONS—OCT1 gene expression and protein levels are
detectable in adipose tissue. Increased OCT1 gene expression in
adipose tissue of obese subjects might contribute to increased
metformin action in these subjects. Diabetes 60:168–176, 2011
M
etformin (dimethylbiguanidine) is the most
widely used drug for the treatment of type 2
diabetes (1,2). This insulin-sensitizing agent
has well known beneﬁcial effects not only on
glycemic control, but also on the cardiovascular system. In
the Diabetes Prevention Program, treatment with met-
formin reduced the incidence of type 2 diabetes by 31%.
Interestingly, metformin was less effective in persons with
a lower baseline BMI than in those with obesity (3). The
reason for this observation is unknown. Shikata et al. (4)
also found that BMI was a strong predictor of metformin
effects: the higher the BMI, the higher the response.
Metformin has been well characterized in vitro as a
substrate of organic cation transporters (OCTs) (5–9).
Members of the OCT family play essential roles in the
handling of cationic drugs and endogenously synthesized
organic cations. Human solute carrier family 22 (organic
cation transporter), member 1 (OCT1) is expressed pri-
marily in the liver, localized in the basolateral membrane
of hepatocytes, mediating the hepatic uptake of several
cationic drugs (metformin, as well as cimetidine, desipra-
mine, midazolam, citalopram, or clonidine). OCT1 has
been reported to be necessary for metabolic activities of
metformin in liver cell lines (10). In fact, different poly-
morphisms in the OCT1 gene have been associated with
metformin action (3).
To our knowledge, OCT1-dependent metformin activity
on other cells has not been previously studied. In addition
to the liver-speciﬁc OCT1, its paralog, human solute
carrier family 22 (organic cation transporter), member 2
(OCT2) is a transporter expressed in abundance in the
kidney (7,8).
The most prominent feature of obesity is increased fat
mass. Despite the important observed effects of metformin
in obesity, there is relatively scarce information about in
vitro models. Metformin effects have been evaluated in the
murine 3T3-L1 cell line, in which an inhibition of adipo-
genesis was found (11–13). To our knowledge, the effects
of this drug on adipogenesis has not been tested in human
preadipocytes despite the potentially important mechanis-
tic effects. However, the effects of metformin (1 mmol/l,
during 24 h) increasing glucose intake in subcutaneous
and visceral human adipocytes have been reported (14).
We ﬁrst observed that metformin inhibited the differen-
tiation of human adipocytes, decreasing the expression of
different lipogenic genes. For this reason, we hypothesized
that OCT1 was mediating these effects. In fact, the inhibi-
tion of this transporter using cimetidine reversed the
blunted differentiation induced by metformin. Finally, we
evaluated the potential in vivo importance of these obser-
vations by studying the expression of OCT1 in human
adipose tissue.
RESEARCH DESIGN AND METHODS
Differentiation of human subcutaneous preadipocytes. Isolated subcuta-
neous preadipocytes from lean (BMI 25) and obese (BMI 30) subjects
(Zen-Bio, Research Triangle Park, NC) were plated on T-75 cell culture ﬂasks
and cultured at 37°C and 5% CO2 in Dulbecco’s modiﬁed Eagle’s medium
(DMEM)/Nutrient Mix F-12 medium (1:1, v/v) supplemented with 10U/ml P/S,
FBS 10%, HEPES 1% and glutamine 1% (all from GIBCO, Invitrogen S.A,
Barcelona, Spain). One week later, the isolated and expanded human subcu-
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2) in 12-well plates
with preadipocytes medium (Zen-Bio) composed of DMEM/Nutrient Mix F-12
medium (1:1, v/v), HEPES, FBS, penicillin and streptomycin in a humidiﬁed
37°C incubator with 5% CO2. Twenty-four hours after plating, cells were
checked for complete conﬂuence (day 0) and differentiation was induced
using differentiation medium (DM, Zen-Bio) composed of preadipocytes
medium, human insulin, dexamethasone, isobutylmethylxanthine and perox-
isome proliferator–activated receptor (PPAR) agonists (rosiglitazone). After
7 days (day 7), DM was replaced with fresh adipocyte medium (AM, Zen-Bio)
composed of DMEM/Nutrient Mix F-12 medium (1:1, v/v), HEPES, FBS, biotin,
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FIG. 1. OCT1, FASN, ACC1, PPAR and adiponectin gene expression during differentiation of human preadipocytes from obese (A) and lean
subjects (B). *P < 0.05 vs. day 0.
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FIG. 2. OCT1 and FASN protein levels in differentiated and
nondifferentiated preadipocytes at day 14. *P < 0.05 vs.
nondifferentiated preadipocytes.
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diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 169panthothenate, human insulin, dexamethasone, penicillin, streptomycin and
amphotericin. Negative control (nondifferentiated cell) was performed with
preadipocyte medium during all differentiation process. Fourteen days after
the initiation of differentiation, cells appeared rounded with large lipid
droplets apparent in the cytoplasm. Cells were then considered mature
adipocytes, harvested, and stored at 80°C for RNA extraction to study OCT1
and OCT2 gene expression levels after human adipocyte differentiation.
Nondifferentiated control was performed using proliferation medium along 14
days. Metformin (Sigma, Barcelona, Spain) (5 mmol/l), cimetidine (Sigma,
Barcelona, Spain) (0.5 mmol/l and 5 mmol/l) and metformin and cimetidine
coincubations were performed with differentiation medium along 14 days. The
experiment was performed in triplicate for each sample. The differentiation
was monitored with the fatty acid synthase (FASN, Hs00188012_m1, Applied
Biosystems, Madrid, Spain), adiponectin (Adipoq, Hs00605917_m1, Applied
Biosystems), acetyl-CoA carboxylase  (ACC1, Hs00167385_m1, Applied Biosys-
tems), peroxisome proliferator-activated receptor  (PPAR, Hs00234592_m1,
Applied Biosystems), fatty acid binding protein 4(FABP4, HS00609791_m1,
Applied Biosystems), interleukin 6 (IL6, Hs00985639_m1, Applied Biosystems),
and monocyte chemoattractant protein-1 (MCP1, Hs00234140_m1, Applied
Biosystems) expression.
Ex vivo experiments using subcutaneous adipose tissue explants.
Subcutaneous adipose tissue was obtained from six obese subjects undergo-
ing open abdominal surgery (gastrointestinal bypass) under anesthesia after
an overnight fast. The mean age was 46  6.4 years (range, 39–58 years) and
the BMI 44.9  12.4 kg/m
2. Medical histories, physical examinations, electro-
cardiogram, and blood screening showed that all patients were in good health.
None of the subjects had a history of hepatic or renal disorders. The study had
the approval of the Ethics Committee and all patients gave informed written
consent.
Samples of subcutaneous adipose tissue were immediately transported to
the laboratory (5–10 min). The handling of tissue was carried out under strict
aseptic conditions. The tissue was cut with scissors into small pieces (5–10
mg), and incubated in buffer plus albumin (3 ml/g of tissue) for 5–30 min.
After incubation, the tissue explants were centrifuged for 30 s at 400 g. Then
100 mg of minced tissue was placed into 1-ml M199 (Gibco, Invitrogen)
containing 10% FBS (Hyclone, Thermo Fisher Scientiﬁc), 100 unit/ml penicillin
(Gibco, Invitrogen), 100 g/ml streptomycin (Gibco, Invitrogen), and incu-
bated for 48 h in suspension culture under aseptic conditions (15). Control
treatment (M199) and metformin (Sigma, Barcelona, Spain) (0.1 and 1 mmol/l)
were compared. After 48 h, all samples were immediately ﬂash-frozen in liquid
nitrogen before being stored at 80°C. To evaluate cell integrity, lactate
dehydrogenase activity released from damaged cells was analyzed by Cyto-
toxicity Detection Kit (lactate dehydrogenase [LDH]; Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s instructions in all
treatments. OCT1, ACC1, FASN, Adipoq, PPAR, IL-6, and MCP-1 relative
gene expression were analyzed using TaqMan technology suitable for relative
genetic expression quantiﬁcation (described below).
Human adipose tissue samples. A group of 118 adipose tissue samples (57
visceral and 61 subcutaneous depots), from participants with a BMI within 20
and 68 kg/m
2, who were recruited at the Endocrinology Service of the Hospital
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FIG. 3. FASN, ACC1, PPAR, adiponectin, OCT1, FABP4, IL-6, MCP-1 gene expressions after metformin (5 mmol/l) and cimetidine (0.5 and 5
mmol/l) cotreatments in differentiated human adipocytes. *P < 0.05 vs. differentiated adipocytes; P < 0.05 vs. metformin (5 mmol/l) treatment.
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were of Caucasian origin and reported that their body weight had been stable
for at least 3 months before the study. Liver and renal diseases were
speciﬁcally excluded by biochemical workup. All subjects gave written
informed consent after the purpose of the study was explained to them.
Adipose tissue samples were obtained from subcutaneous and visceral
depots during elective surgical procedures (cholecystectomy, abdominal
hernia surgery, and gastric by-pass surgery). All samples were washed,
fragmented, and immediately ﬂash-frozen in liquid nitrogen before stored at
80°C.
To perform the isolation of adipocyte and stromo-vascular fraction, tissues
were washed three to four times with PBS and suspended in an equal volume
of PBS supplemented with 1% bovine serum and 0.1% collagenase type I
prewarmed to 37°C. The tissue was placed in a shaking water bath at 37°C
with continuous agitation for 60 min, and centrifuged for 5 min at 300 to 500g
at room temperature. The supernatant, containing mature adipocytes, was
recollected. The pellet was identiﬁed as the SVF cell. The adipose tissue
fractionation was performed from eight subcutaneous fat depots.
RNA expression. To study gene expressions, RNA was prepared from these
samples using RNeasy Lipid Tissue Mini Kit (Qiagen,Izasa SA, Barcelona,
Spain). The integrity of each RNA sample was checked by Agilent Bioanalyzer
(Agilent Technologies, Palo Alto, CA). Total RNA was quantiﬁed by means of
spectrophotometer (GeneQuant, GE Health Care, Piscataway NJ) reverse
transcribed to cDNA using a High Capacity cDNA Archive Kit (Applied
Biosystems) according to the manufacturer’s protocol.
Gene expression was assessed by real time PCR using an ABI Prism 7,000
Sequence Detection System (Applied Biosystems, Madrid, Spain), using
TaqMan technology suitable for relative genetic expression quantiﬁcation.
The commercially available and prevalidated TaqMan primer/probe sets
used were as follows: endogenous control PPIA (4333763, cyclophilin A,
Applied Biosystems, Madrid, Spain) and target gene human organic cat-
ion transporter 1 and human organic cation transporter 2 (OCT1,
Hs00427552_m1; and OCT2, Hs00161893_m1, Applied Biosystems). The RT-
PCR TaqMan reaction was performed in a ﬁnal volume of 25 l. The cycle
program consisted of an initial denaturing of 10 min at 95°C, and then 40
cycles of 15-s denaturizing phase at 95°C and 1 min annealing and extension
phase at 60°C. A threshold cycle (Ct value) was obtained for each ampliﬁca-
tion curve, and a 	Ct value was ﬁrst calculated by subtracting the Ct value for
human Cyclophilin A (PPIA) RNA from the Ct value for each sample. Fold
changes compared with the endogenous control were then determined by
calculating 2
	Ct, so gene expression results are expressed as expression
ratios relative to PPIA gene expression according to manufacturers’
guidelines.
Western blot analysis. Adipose tissue lysates (from eight subcutaneous fat
depots) were washed in ice-cold PBS followed by homogenization assay using
RIPA lysis buffer (Millipore, Madrid, Spain) supplemented with a protease
inhibitor cocktail (Sigma-Aldrich, Madrid, Spain) at 4°C for 30 min. Cellular
debris were eliminated by centrifugation of the diluted samples at 14,000 g for
30 min (4°C). Protein concentration was determined using a Lowry assay.
RIPA protein extracts (50 g) were separated by SDS-PAGE and transferred
to nitrocellulose membranes by conventional procedures. Membranes were
immunoblotted with OCT1, FASN, and 
-actin antibodies (Santa Cruz Bio-
technology, CA). Anti-rabbit IgG and anti-mouse IgG coupled to horseradish
peroxidase was used as a secondary antibody. Horseradish peroxidase
activity was detected by chemiluminescence, and quantiﬁcation of protein
expression was performed using scion image software.
AMPK and acetyl-CoA carboxylase- activity. AMP-activated protein
kinase (AMPK) activity was determined measuring pThr172AMPK by ELISA
(KHO0651, Invitrogen, Barcelona, Spain). pThr172AMPK is directly associated
with AMPK activity. According to the manufacturer, the analytical sensitivity
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FIG. 4. Oil red O staining and LDH activity in differentiated human adipocytes, and after metformin (5 mmol/l) and cimetidine (0.5 and 5 mmol/l)
cotreatment. *P < 0.05 vs. differentiated adipocytes; P < 0.05 vs. metformin (5 mmol/l) treatment. (A high-quality color representation of this
ﬁgure is available in the online issue.)
J.M. MORENO-NAVARRETE AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 171of this assay is 1 unit/ml of AMPK [pT172]. This was determined by adding
two SDs to the mean O.D. obtained when the zero standard was assayed 30
times. The average recovery was 90% The speciﬁcity of this assay for
phosphorylated AMPK (pT172) was conﬁrmed by peptide competition. Intra-
and interassay coefﬁcients of variation for all these determinations were
between 5 and 10%.
Acetyl-CoA carboxylase- (ACC) activity was calculated measuring
pSer79ACC1 and ACC1 (total) by ELISA (KHO1061 and KHO1071, respec-
tively; Invitrogen, Barcelona, Spain). pSer79ACC1 is inversely associated with
ACC activity. The analytical sensitivity of these assays are 0.5 units/ml of
human ACC1 [pS79] and human ACC1, respectively. These were determined
by adding two SDs to the mean O.D. obtained when the zero standards was
assayed 30 times. The percentage recovery was calculated as an average of 93
and 97%, respectively. The speciﬁcity of this assay for phosphorylated ACC1
[pS79] was conﬁrmed by peptide competition. Intra- and interassay coefﬁ-
cients of variation for all these determinations were between 5 and 10%.
Oil Red staining and analysis. Differentiation was monitored by morpho-
logic assessment and Oil red O staining. For Oil Red staining, cells were
washed twice with PBS, ﬁxed in 4% formaldehyde for 1 h, and stained for 30
min with 0.2% Oil Red O solution in 60% isopropanol. Cells were then washed
several times with water, and excess water was evaporated by placing the
stained cultures at 32°C. To determine the extent of adipose conversion, 0.2
ml of isopropanol was added to the stained culture dish. The extracted dye
was immediately removed by gentle pipeting and its optical density was
monitored spectrophotometrically at 500 nm using a multiwell plate reader
(Model Anthos Labtec 2010 1.7 reader).
Cell counting and LDH activity assay. Cell counting was assessed by
trypan blue dye exclusion using a Neubauer hemacytometer, after 14 days
differentiation of human subcutaneous preadipocytes, in triplicate.
To evaluate cell integrity, LDH activity released from damaged cells was
analyzed by Cytotoxicity Detection Kit (LDH; Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instructions.
Statistical analyses. Statistical analyses were performed using SPSS 12.0
software. Unless otherwise stated, descriptive results of continuous variables
are expressed as mean and SD for Gaussian variables, or median and
interquartile range. Parameters that did not fulﬁll normal distribution were
mathematically transformed to improve symmetry for subsequent analyses.
The relation between variables was analyzed by simple correlation (Spearman
test). Unpaired and paired t tests were used to compare clinical variables and
OCT-1 and 2 gene expressions according to obesity status. Nonparametric
tests, Mann Whitney U and Wilcoxon’s tests, were used to evaluate the effects
of metformin and cimetidine treatments in vitro and ex vivo. The experiments
were performed in triplicate.
RESULTS
OCT-1 and OCT-2 expression during differentiation
of human preadipocytes. The differentiation process
was monitored through FASN, ACC1, PPAR, and Adipoq
gene expression (Fig. 1), with accumulation of lipid drop-
lets in the cytoplasm.
In isolated preadipocytes from lean and obese subjects,
OCT1 gene expression was signiﬁcantly increased during
the differentiation process in parallel to adipogenic genes
(Fig. 1). In differentiated preadipocytes OCT1 protein
levels were signiﬁcantly higher than in nondifferentiated
preadipocytes (Fig. 2). OCT2 gene expression was very
small and disappeared during adipogenesis.
OCT1 gene expression was positively associated with
FASN (r  0.8, P  0.001), ACC1 (r  0.66, P  0.003),
PPAR (r  0.65, P  0.004) and Adipoq (r  0.73, P 
0.001) gene expressions and negatively with IL-6 gene
expression (r  0.7, P  0.002).
Metformin effects on adipogenesis and AMPK activ-
ity. Metformin (5 mmol/l) decreased the expression of
lipogenic genes (Fig. 3) and lipid droplets accumulation
(Fig. 4), leading to impaired differentiation of human
preadipocytes. Cotreatment with cimetidine restored adi-
pogenesis (Fig. 3).
Proinﬂammatory molecules, such as IL-6 and MCP-1,
signiﬁcantly decreased during adipocyte differentiation.
However, metformin administration did not increase IL-6
and MCP-1 gene expression in comparison with differen-
tiated adipocytes. The decreased levels of expression of
proinﬂammatory molecules were maintained with cimetidine
cotreatment. High doses of cimetidine (5 mmol/l) signiﬁ-
cantly decreased adiponectin gene expression (Fig. 3).
OCT1 gene expression did not change signiﬁcantly after
metformin or cimetidine treatments (Fig. 3).
Metformin treatment increased signiﬁcantly AMPK activ-
ity, increasing
p172ThrAMPK and consequently
p79SerACC1. In
cimetidine coincubation, the increase of AMPK activity was
blunted (Fig. 5). The total ACC1 quantiﬁcation showed a
similar expression pattern to ACC1 gene expression.
LDH activity was measured to evaluate the cytotoxicity
in each of the treatments. No signiﬁcant difference was
found comparing undifferenciated and differenciated adi-
pocytes, whether treated or untreated with cimetidine (0.5
mmol/l and 5 mmol/l). After metformin (5 mmol/l) treat-
ment, LDH activity tended to be higher compared with
differentiated adipocytes (Fig. 4).
Metformin effects in subcutaneous adipose tissue
explants. Metformin (0.1 and 1 mmol/l) led to decreased
adipogenic and inﬂammatory gene expression (Fig. 6).
OCT1 gene expression was not affected by metformin
administration (Fig. 6).
In addition, baseline OCT1 gene expression was associ-
ated with the metformin-induced adipogenic gene expres-
sion reduction (ACC1, Adipoq, FASN, and PPAR),
suggesting that the higher the OCT-1 gene expression, the
Differentiation   - +                +              +              +   
Metformin (5 mM)      - - +              +              +
Cimetidine (0.5 mM)   - - - +               -
Cimetidine (5mM) - - - - + 
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 0.81,
P  0.04, r  0.94, P  0.004, r  0.96, P  0.002 and
r  0.68, P  0.1, respectively; and for 1 mmol/l, r 
0.76, P  0.07, r  0.94, P  0.004, r  0.88, P  0.02,
and r  0.64, P  0.17, respectively).
Treatment of adipose tissue with metformin (0.1 and 1
mmol/l) did not change lactate dehydrogenase activity (cell
integrity) in comparison with control treatment (Fig. 6).
OCT1 and OCT2 expression in human adipose tissue.
Anthropometric and clinical characteristics of all partici-
pants are shown in Table 1. The OCT1 gene was similarly
expressed in subcutaneous and visceral adipose tissue
[0.002 (0.0005–0.0034) versus 0.0015 (0.0004–0.003) R.U.,
P  0.4, n  31]. In fact, the expression of OCT1 in both
fat depots correlated signiﬁcantly (r  0.54, P  0.001).
The relative OCT1 gene expression was lower compared
with lipogenic genes (100- and 10-fold decrease in com-
parison with FASN and ACC1 gene expression). In both
subcutaneous and visceral fat depots, OCT1 gene expres-
sion correlated signiﬁcantly with BMI (r  0.46, P  0.001
and r  0.47, P  0.001, respectively) and percent fat mass
(r  0.36, P  0.005, and r  0.49, P  0.001, respectively)
(Fig. 7). In addition, OCT1 gene expression correlated
signiﬁcantly with diastolic blood pressure (r  0.35, P 
0.04) in visceral adipose tissue. No associations were
detected with other metabolic parameters (age, systolic
blood pressure, fasting glucose, fasting triglycerides, HDL
cholesterol, and LDL cholesterol).
There is evidence indicating that mRNA levels may not
necessarily predict the translated protein levels. In this
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Western blot. OCT1 protein was signiﬁcantly increased in
obese subjects (Fig. 8A).
To gain insight about the type of cells from adipose
tissue that expressed OCT1, we analyzed OCT1 gene
expression in stromo-vascular cells and mature adipocytes
from subcutaneous adipose tissue. In stromo-vascular
cells OCT1 gene expression was signiﬁcantly higher than
in mature adipocytes (1.8-fold increase, P  0.01; Fig. 8B).
The OCT2 gene was not signiﬁcantly expressed in
human adipose tissue.
DISCUSSION
Metformin has been described to be more effective in
obese subjects, and the degree of obesity has been found
to constitute a strong predictor of metformin effects (3,4).
The main ﬁndings of this study are: 1) OCT1 gene expres-
sion was detectable in whole adipose tissue (similarly in
the subcutaneous and visceral fat depots) and in isolated
adipocytes; 2) this expression increased signiﬁcantly with
adipocyte differentiation in association with lipogenic
(FASN, ACC, PPARg) and adipogenic (Adipoq) genes; 3)
metformin (5 mmol/l) blunted the adipocyte differentiation
of human preadipocytes in parallel to decreasing signiﬁ-
cantly the expression of proinﬂammatory mediators; 4)
blocking metformin action using cimetidine reversed these
effects; and 5) In ex-vivo experiments, metformin led to
decreased adipogenic and proinﬂammatory gene expres-
sion. To the best of our knowledge, this is the ﬁrst study
evaluating metformin effects and OCT1 gene expression in
human adipocytes. The increased OCT1 gene expression
in stromo-vascular cells compared with adipocytes sug-
gests that metformin action on stromo-vascular cells might
contribute to systemic effects. Considering the importance
of OCT1 in the metformin response (9), we suggest that
the higher OCT1 gene expression in obese subjects is
behind the increased metformin effects in these subjects.
Interestingly we found that baseline OCT1 gene expres-
sion was associated with the metformin-induced adipo-
genic gene expression reduction (ACC1, Adipoq, FASN
and PPAR), suggesting that the higher the OCT-1 gene
expression, the higher the effects of metformin.
The inhibitory effects of metformin on adipogenesis
have been previously shown in the 3T3-L1 cell line (11–13)
via AMPK activation. However, to our knowledge, these
actions have not been explored in human preadipocytes.
In the current study, metformin (5 mmol/l) signiﬁcantly
decreased the expression of adipogenic (FASN, ACC,
TABLE 1
Anthropometrical and biochemical variables of study participants
Not obese Obese
Obese with
type 2 diabetes P
N 15 32 14
Sex (men/women) 5/10 9/23 2/12
Age (years) 47.4  10.4 44.1  9.7 46.6  12.4 0.4
BMI (Kg/m
2) 26.57  2.34 41.7  7.6 41.4  4.1 0.001
Fat mass (%) 33.5  4.98 51.3  10.6 53.5  4.9 0.001
SBP (mmHg) 125  15.5 133.4  20.4 141.4  26.8 0.05
DBP (mmHg) 78.5  9.8 77.1  10.55 77.47  9.98 0.4
Fasting glucose (mg/dl) 87.2  11.5 93.29  11.3 132.57  46.2 0.001
Fasting triglycerides (mg/dl) 112.3  54.04 112.6  66.9 123.85  39.1 0.7
HDL cholesterol 69.07  29.3 52.9  18.14 54.9  13.5 0.01
LDL cholesterol 98.4  37.1 110.02  30.9 121.5  25.1 0.1
OCT1 gene expression in SAT (relative units) 0.0005 (0.00008–0.005) 0.0015 (0.00001–0.004) 0.002 (0.0003–0.012) 0.002*
OCT1 gene expression in VAT (relative units) 0.0006 (0.0002–0.006) 0.0026 (0.0001–0.015) 0.0027 (0.0002–0.005) 0.02*
Values are mean  SD. *Comparing obese subjects vs. nonobese. Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.
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increasing AMPK activity (
p172ThrAMPK and consequently
p79SerACC1). The adipocyte differentiation (increasing lipo-
genic gene expression and decreasing AMPK activity) was
restored dose-dependently when the OCT1 blocker agent
cimetidine was used as a cotreatment.
In agreement with our data, the response to metformin
was inhibited in mice models in which the OCT1 gene was
deleted (OCT1
/). Subjects carrying a single nucleotid
polymorphism associated with a decrease in OCT1 gene
expression also showed decreased metformin effects
(4,10,16).
Importantly, metformin administration signiﬁcantly de-
creased IL-6 and MCP-1 gene expression in adipocytes and
in adipose tissue explants. Recently, metformin has been
shown to display anti-inﬂammatory effects in endothelial
cells by inhibiting TNF-–induced IKK/
 phosphoryla-
tion, IkappaB- degradation, and IL-6 production (17,18).
The mode of action of metformin has yet to be fully
established. In muscle, liver, and endothelial cells, the
metabolic changes induced by metformin appear to be
mediated by the AMP-activated protein kinase (AMPK).
AMPK acts as a sensor of the cellular energy status, being
switched on by an increased ATP demand or by processes
that interfere with ATP production such as ischemia. The
activated form of AMPK switches on catabolic pathways
while switching off ATP-consuming processes (19). It has
been reported that metformin binds to complex I of the
mitochondrial respiratory chain, and this could in part
explain how this drug acts (20). The inhibition of complex
I would cause a decrease in energy supply that would in
turn lead to a higher AMP/ATP ratio, and the concomitant
activation of AMPK. It seems counterintuitive that met-
formin is providing a beneﬁcial effect by attenuating
adipocyte differentiation. However, although metformin
has been associated with weight loss, glitazones lead to
increased adipocyte differentiation and weight gain. Met-
formin stimulates catabolic pathways in white adipose
tissue through the activation of AMPK, reducing the tri-
glyceride stores as reﬂected by the smaller size of the
adipocytes (13,21). These effects are achieved through an
increase in lipolysis and 
-oxidation, which would imply
that there is no release of fatty acids and that they are
oxidized within the adipocyte. Other authors have de-
scribed that metformin inhibited adipocyte differentiation
(using rat mesenchymal stem cells) (22). We propose here
that OCT1 density in adipose tissue is a factor that can
signiﬁcantly inﬂuence all these effects of metformin. Fur-
thermore, Fisher et al. (14) have shown that metformin
induces glucose uptake independent of insulin in subcuta-
neous and visceral human adipocytes.
In conclusion, OCT1 gene expression and protein levels
are detectable in adipose tissue. The increased OCT1 gene
expression in adipose tissue of obese subjects might
contribute to increased metformin action in these
subjects.
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